Johnson And Johnson Continues To Focus On Medical Innovation
Johnson And Johnson Continues To Focus On Medical Innovation
On Wednesday, Johnson & Johnson (NYSE:JNJ) reported its second quarter results that reflected a strong momentum of its medtech and innovative medicine divisions. Although one-time charges prevented topline growth from reaching the bottom line, Johnson and Johnson showed it continues to advance its drug pipeline for a new medical era, with significant clinical milestones being attained throughout the quarter.
周三，强生公司（纽交所：JNJ）公布了其第二季度财报，反映了其医疗技术和创新药物部门的强势势头。尽管一次性费用阻止了收入增长达到底线，但强生公司表明其继续推进新医疗时代的药物管线，整个季度取得了重大的临床里程碑。
Second Quarter Highlights
二季度亮点
For the June quarter, Johnson & Johnson reported topline growth of 4.3% YoY as sales grew to $22.45 billion, surpassing the FactSet consensus of $22.33 billion. Regionally, U.S. sales grew 7.8% YoY, bringing in $12.5 billion, while international sales remained flat at $9.8 billion.
就6月季度而言，强生公司报告了4.3%的年度收入增长，销售额增长至224.5亿美元，超过FactSet的预期223.3亿美元。在地区方面，美国的销售额同比增长了7.8%，达到了125亿美元，而国际销售额保持在98亿美元的水平。
Fueled by cancer drug Darzalex among other growth drivers, the innovative medicine segment recorded sales growth of 5.5%, bringing in revenue of $14.49 billion, also topping FactSet consensus of $14.12 billion.
在癌症药物Darzalex等增长驱动因素的推动下，强生公司的创新药物部门销售增长了5.5%，营业收入达到了144.9亿美元，也超过了FactSet的预期141.2亿美元。
The medtech division grew 2.2% to $7.96 billion, coming short of Fact Set's consensus of $8.17 billion
医疗技术部门增长了2.2%，达到了79.6亿美元，而Fact Set的预期为81.7亿美元。
As for Johnson & Johnson's best-selling drugs, psoriasis treatment Stelara recorded growth of 3.1% to $2.89 billion, surpassing FactSet consensus of $2.85 billion, while cancer treatment Darzalex recorded 18.4% growth with sales rising to to $2.878 billion, also slighly below the expected $2.885 billion.
至于强生公司最畅销的药物，治疗牛皮癣的Stelara的销售额增长了3.1%，达到了28.9亿美元，超过了FactSet的预期28.5亿美元，而治疗癌症的Darzalex的销售额录得18.4%的增长，销售额达到了28.78亿美元，略低于预期的28.85亿美元。
On the other hand, infectious disease drugs recorded a 13.9% drop with sales amounting to $965 million, while COVID-19 vaccine sales plummeted even more, falling 40% to $172 million.
另一方面，传染病药物的销售额下降了13.9%，销售额为9650万美元，而新冠疫苗的销售额更是暴跌了40%，降至1720万美元。
Due to one-time charges, net earnings fell almost 13% to $4.6 billion, with earnings per share dropping nearly 6% to $1.93. But adjusted for one-time items, EPS actually rose by 10.2% to $2.82.
由于一次性费用的影响，净收入几乎下降了13%，每股收益也下降了近6%，降至1.93美元。但在排除一次性项目后，每股收益实际上上升了10.2%，达到了2.82美元。
Slightly altered full year guidance
细微调整的全年指引
J&J raised the midpoint of its full-year guidance for operational sales from a $88.9 billion to $89.4 billion, fueled by the completion of the $13.1 billion acquisition of its newest medtech conquest, Shockwave Medical. But, due to the costs of this strategic acquisitions, it also lowered its full-year adjusted operational EPS guidance that are now expected in a range from $10 to $10.10.
强生公司将全年经营性销售指引中点从889亿美元上调至894亿美元，该数字受益于新收购的医疗科技公司Shockwave Medical的131亿美元收购。但由于这些战略收购的成本，因此强生公司也将其全年经调整后的经营性每股收益指引下调到10至10.10美元的区间。
The second quarter performance reflects focus on medical innovation.
第二季度业绩反映了对医疗创新的关注。
Throughout the quarter, the health care bellwether was busy with M&A. Besides completing the Shockwave deal, it scooped up bispecific antibodies biotech Proteologix for $850 million in cash. Johnson and Johnson also spent $1.25 billion to get Numab Therapeutics' experimental bispecific antibody that targets atopic dermatitis. In addition, J& J also had a few activities of the regulatory front during the quarter. Carvykti was greenlit by the Food and Drug Administration for second-line use in adults with relapsed refractory multiple myeloma, which J&J developed with Legend Biotech's. J&J also submitted an application to treat moderately to severely active Crohn's disease with Tremfya.
整个季度，这家医疗行业的风向标公司忙于进行并购。除了完成Shockwave交易外，它还以现金支付8.5亿美元收购了双特异性抗体生物技术公司Proteologix。强生公司还花费12.5亿美元收购了Numab Therapeutics的试验性双特异性抗体，该抗体针对特应性皮炎。此外，强生在本季度还在监管方面进行了一些活动。Carvykti获得了食品和药品监督管理局的批准，用于治疗成人复发难治性多发性骨髓瘤病患者的二线治疗，该药由传奇生物和强生公司共同开发。强生公司还提交了一份申请，用于治疗中度至严重活动性克罗恩病的Tremfya。
DISCLAIMER: This content is for informational purposes only. It is not intended as investing advice.
免责声明：本内容仅供参考，不构成任何投资建议。
This article is from an unpaid external contributor. It does not represent Benzinga's reporting and has not been edited for content or accuracy.
本文来自非报酬的外部投稿人。它不代表Benzinga的报道，并且没有因为内容或准确性而被编辑。